Edward Agura, MD | Authors

Articles

A Phase III Trial Evaluating Iomab-B Prior to HCT in Relapsed/Refractory AML

December 13, 2018

Edward Agura, MD, Texas Oncology - Baylor Charles A. Sammons Cancer Center Blood and Marrow Transplant, discusses the phase III SIERRA trial, which is an ongoing trial investigating targeted conditioning of Iomab-B prior to allogeneic hematopoietic cell transplantation versus conventional care in patients with relapsed/refractory acute myeloid leukemia (AML).